Anti-cancer drug price reduction curtain opened, the highest drop of up to 51.6%

The State Health Insurance Administration said recently that with the new anti-cancer drug regulations gradually landing, the Bureau is actively implementing the follow-up measures to reduce taxes on anti-cancer drugs, through the implementation of special tender procurement, access negotiations with enterprises, negotiations to determine a reasonable price and other measures to urge the promotion of anti-cancer drugs to speed up price reduction.
fact, timetables and road maps are already in the fore. On July 11, Vice Premier Han Zheng gave a close-up of the "Special Work Schedule for Anti-Cancer Drugs" when the news of the investigation by the State Health Insurance Administration aired. "Progress Schedule" shows that the special work on the price reduction of anti-cancer drugs has been carried out since June 1, divided into "the first 17 anti-cancer drug kinds of interviews" and "out-of-catalog anti-cancer drug access negotiations" two work to advance simultaneously;17 anti-cancer drugs will be the first to reduce prices
" through the first two national negotiations, has entered the health insurance list of 17 anti-cancer drugs, will soon usher in a new round of price cuts. A business source told reporters that shortly after the tax cut, the State Health Insurance Administration on the above-mentioned drugs began to organize a new round of price negotiations, "at present, most of the relevant enterprises have begun to carry out new cost and price measurement." According to the Schedule arrangement, this work has been held a corporate symposium, the deployment of tax reform price adjustment calculation, and then will organize financial and tax experts to review, and through the review of the enterprise signed a supplementary agreement to guide enterprises to timely announce new prices, mature one, publish one, by the end of August to complete all varieties of tax reform price adjustment.
it is worth mentioning that of these 17 drugs, the targeted drug gyfeitinib, used to treat local late stage or metastasis non-small cell lung cancer, has been produced by an enterprise of domestic generic drugs through consistent evaluation. After national negotiations, the price of Ginistini tablets produced by AstraZeneta fell to 2,358 yuan, while the price of domestic generic drugs evaluated by consistency is about 1,600 yuan;
Schedule also shows that the out-of-catalog anti-cancer drug access negotiations, has now completed the final work programme, out-of-catalog anti-cancer drug situation mapping, the establishment of a review expert group and other work, the next step will be to organize expert review, propose alternatives and determine the proposed drug negotiations;the maximum number of drugs reduced by more than 50
In addition to the above-mentioned state-led negotiations on innovative drugs, patented drugs to reduce prices, many other cancer drugs due to the new tax reform of the price reduction space should be implemented? Imatinil, Tisitabin, yew alcohol injections and many other cancer drugs already on the health insurance list face a more complex market landscape.
of July, Pfizer, Xi'an Yangsen and other pharmaceutical companies have been in Gansu, Beijing, Hubei and other places to take the initiative to reduce the price of some drugs, involving a number of anti-cancer drugs.
July 2, Xi'an Yangsen took the lead in announcing that xitabin, the injection site used to treat bone marrow growth syndrome, would be reduced from 10,327.22 yuan to 4,996 yuan, a decrease of 51.6%. Reporters consult the data found that there are currently 7 domestic enterprises producing West Talbin generic drugs, there are a variety of specifications of products on the market;
then, Pfizer voluntarily lowered the prices of 20 drugs, including yew alcohol injections, ketini capsules, by 3.8% to 10.2%, with the yew alcohol injection (5 ml/30 mg) dropping from 793 yuan to 746.85 yuan. According to the website of the State Drug Administration, there are 63 generic drug approvals in China, involving dozens of enterprises;
July 5, Jiangsu Haussen Pharmaceuticals announced that its production of imatini tablets has been successfully evaluated by generic drug consistency, and on July 9, Novarian, Switzerland, the original research products in Shenzhen Public Hospital Pharmaceutical Group procurement prices, but did not announce a specific reduction. Previously, although four domestic enterprises have produced generic drugs listed, the price is more than 800 yuan to 1200 yuan, but the price of the original research products has been strong in more than 10,000 yuan. (Chongqing Morning Post)